[1]隋宾艳,赵 琨.肝细胞癌患者术后辅助CIK细胞免疫治疗的成本效果分析[J].卫生经济研究,2018,(10):6-9.
　SUI Bin-yan,ZHAO Kun.Cost-effectiveness Analysis of Adjuvant CIK Cell Immunotherapy of Post-operative Patients with Hepatocellular Carcinoma[J].Journal Press of Health Economics Research,2018,(10):6-9.
点击复制

肝细胞癌患者术后辅助CIK细胞免疫治疗的成本效果分析
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2018年10期
页码:
6-9
栏目:
卫生技术评估
出版日期:
2018-10-05

文章信息/Info

Title:
Cost-effectiveness Analysis of Adjuvant CIK Cell Immunotherapy of Post-operative Patients with Hepatocellular Carcinoma
作者:
隋宾艳1; 赵 琨2
1.北京师范大学社会发展与公共政策学院，北京 100875
2.国家卫生计生委卫生发展研究中心，北京 100191
Author(s):
SUI Bin-yan;  ZHAO Kun
School of Social Development and Public Policy, Beijing Normal University, Beijing 100875, China
关键词:
细胞免疫治疗; 成本效果分析; 肝细胞癌患者
Keywords:
cell immunotherapy;  cost-effectiveness analysis;  patients with hepatocellular carcinoma
分类号:
R19
文献标志码:
A
摘要:
本文基于我国卫生服务体系，构建了一个基于Markov队列的决策分析模型，比较肝细胞癌手术后患者开展辅助CIK治疗相对于不开展CIK辅助治疗的成本效果。结果显示：按年贴现率3%计算，手术后辅助CIK治疗与单纯手术治疗相比，可获得1.49个QALYs 的额外收益，其相应花费的额外成本为131 912.43元，增量成本效果比为88 927.49元/QALY。根据WHO关于低于3倍人均GDP的成本效果阈值设定，对术后肝细胞癌患者而言，辅助CIK治疗是具有成本效果的新治疗方案。
Abstract:
Based on China's health service system, this paper constructed a Markov-based decision-making analysis model to compare the cost-effectiveness of post-operative patients with hepatocellular carcinoma with adjuvant CIK cell immunotherapy compared those without. The results showed that after the annual discount rate of 3%, the post-operative adjuvant CIK treatment can obtain an additional benefit of 1.49 QALYs compared with the simple surgery. The additional cost of the corresponding cost was 131 912.43 RMB, and the incremental cost-effectiveness ratio was 88 927.49 RMB / QALY. According to WHO's cost effectiveness threshold setting that less than 3 times GDP per capita, adjuvant CIK treatment is a cost-effective new treatment option for post-operative patients with hepatocellular carcinoma.

参考文献/References:

[1] 吕静静，李仁鹏，徐爱强，等.山东省乙型肝炎病毒感染相关疾病住院患者经济负担及影响因素分析[J].中华流行病学杂志,2013,34(3):267-272.
[2] 石菊芳，石春磊，岳馨培，等.1996—2014年中国恶性肿瘤经济负担的系统评价[J].中华肿瘤杂志，2016，38(12)：929-941.
[3] Xie,F, et al.Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS One, 2012,7(8): e42879.
[4] 刘国恩.中国药物经济学评价指南及导读[M].北京: 科学出版社，2015.
[5] Pan, K, et al.The Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Therapy for Postoperative Hepatocellular Carcinoma Patients[J]. Annals of Surgical Oncology, 2013,20(13):4305-4311.
[6] Almeida, A.M,et al.Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine[J]. Value Health, 2011,14(5 Suppl 1): p. S24-28.
[7] Hoshida, Y, Y. Shiratori, and M. Omata.Cost-effectiveness of adjuvant interferon therapy after surgical resection of hepatitis C-related hepatocellular carcinoma[J].Liver, 2002,22(6):479-485.
[8] Mo, H.-Y, Y.-Y. Liao, and X.-M. You.Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy. 2017.
[9] Lee, J.H, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology, 2015.
[10] Levy, A.R, et al.The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons[J]. Value Health, 2008,11(3):527-538.
[11] 国家卫生和计划生育委员会.2015中国卫生和计划生育统计年鉴[M].北京: 中国协和医科大学出版社，2015.
[12] 吕静静，李仁鹏，徐爱强，等.山东省乙型肝炎病毒感染相关疾病住院患者经济负担及影响因素分析[J]. 中华流行病学杂志,2013，34(3):267-272.

相似文献/References:

[1]邱英鹏,肖 月,史黎炜,等.内窥镜手术器械控制系统辅助治疗的成本效果分析[J].卫生经济研究,2018,(06):13.
[2]李园园,杜灵彬,王悠清,等.浙江省食管癌筛查的经济学评价——以生命年为效果指标[J].卫生经济研究,2022,39(3):18.
　LI Yuan-yuan,DU Ling-bin,WANG You-qing,et al.Economic Evaluation of Esophageal Cancer Screening in Zhejiang Province——Take Life Year as the Effect Index[J].Journal Press of Health Economics Research,2022,39(10):18.
[3]姜 巍,刘亭亭,董亚丽,等.“糖尿病诊疗适宜技术培训”策略的成本效果分析[J].卫生经济研究,2022,39(5):21.
　JIANG Wei,LIU Ting-ting,DONG Ya-li,et al.Cost-Effectiveness Analysis of Training of Appropriate Technologies for Managing Diabetes[J].Journal Press of Health Economics Research,2022,39(10):21.
[4]汤雅倩,赵明烨,唐文熙.信迪利单抗对比卡瑞利珠单抗一线治疗 晚期非鳞状非小细胞肺癌的经济学评价[J].卫生经济研究,2023,40(2):34.
　TANG Yaqian,ZHAO Mingye,TANG Wenxi.Pharmacoeconomic Evaluation of Sintilimab Versus Camrelizumab in the First-Line Treatment of Patients with Non-Squamous Advanced Non-Small Cell Lung Cancer in China[J].Journal Press of Health Economics Research,2023,40(10):34.

更新日期/Last Update: 2018-09-29